Drug
F-18 AV 1451
F-18 AV 1451 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (33.3%)
N/A2 (66.7%)
Trials by Status
active_not_recruiting133%
completed133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingnot_applicable
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
NCT02605785
active_not_recruitingnot_applicable
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
NCT02740634
completedphase_1
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
NCT02736695
Clinical Trials (3)
Showing 3 of 3 trials
NCT02605785Not Applicable
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
NCT02740634Not Applicable
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
NCT02736695Phase 1
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3